Pentobarbital will decrease the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease Sopra fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome Durante a patient who has developed https://7bookmarks.com/story20171544/indicatori-sulla-pentobarbital-si-deve-sapere